Methods of inhibiting TNFα in patients with cancer
US7169388B2 · kind B2 · utility
15Cited by
36References
26Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 30, 2004 |
| Grant date | Jan 30, 2007 |
| Priority date | — |
| Expiry date | Sep 30, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.